Prothionamide: Difference between revisions
CSV import |
CSV import |
||
| Line 28: | Line 28: | ||
[[Category:Tuberculosis]] | [[Category:Tuberculosis]] | ||
{{medicine-stub}} | {{medicine-stub}} | ||
<gallery> | |||
File:Protionamide.svg|Prothionamide chemical structure | |||
File:Prothionamide_3D_ball.png|Prothionamide 3D ball model | |||
</gallery> | |||
Latest revision as of 01:52, 17 February 2025
Prothionamide is a thioamide antibiotic used primarily in the treatment of tuberculosis (TB). It is considered a second-line drug, meaning it is often used when the first-line drugs (such as isoniazid and rifampicin) are not effective or cannot be used due to the presence of drug-resistant TB strains or because of patient intolerance to these medications. Prothionamide works by inhibiting the synthesis of mycolic acid, an essential component of the mycobacterial cell wall.
Mechanism of Action[edit]
Prothionamide exerts its antibacterial effects through the inhibition of mycolic acid synthesis. Mycolic acids are long-chain fatty acids found in the cell walls of Mycobacterium species, including Mycobacterium tuberculosis, the bacterium responsible for tuberculosis. By disrupting the production of these acids, prothionamide compromises the integrity of the bacterial cell wall, leading to cell death.
Indications[edit]
Prothionamide is used in the treatment of active and multidrug-resistant (MDR) tuberculosis. It is often part of a combination therapy regimen, as the use of multiple drugs reduces the risk of developing further drug resistance. Prothionamide may also be considered in cases of leprosy resistant to other treatments.
Pharmacokinetics[edit]
The pharmacokinetics of prothionamide involve its absorption from the gastrointestinal tract, metabolism in the liver, and excretion primarily through the urine. The drug is metabolized by various pathways, including hydroxylation and deamination, leading to the formation of active and inactive metabolites.
Adverse Effects[edit]
The use of prothionamide can be associated with several adverse effects. These include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as neurological symptoms like peripheral neuropathy. Hepatotoxicity, manifesting as elevated liver enzymes and jaundice, is another significant concern. To mitigate some of these side effects, prothionamide is often administered with pyridoxine (vitamin B6).
Drug Interactions[edit]
Prothionamide can interact with other medications, potentially altering their effects. For example, its use with other hepatotoxic drugs can increase the risk of liver damage. Additionally, prothionamide may enhance the effects of hypoglycemic agents, necessitating adjustments in their dosages.
Dosage and Administration[edit]
The dosage of prothionamide varies depending on the patient's age, weight, and the severity of the infection. It is typically taken orally, with doses adjusted based on the patient's response and the occurrence of adverse effects.
Resistance[edit]
As with other antibiotics, the emergence of resistance to prothionamide is a concern. Resistance occurs through genetic mutations in the mycobacterium that reduce the drug's efficacy. To combat resistance, prothionamide is used in combination with other antitubercular drugs.
Conclusion[edit]
Prothionamide is a valuable second-line drug in the treatment of tuberculosis, particularly in cases of drug-resistant TB. Despite its potential for adverse effects and interactions, when used judiciously in combination therapy, it remains an important tool in the global fight against tuberculosis.
-
Prothionamide chemical structure
-
Prothionamide 3D ball model
